|
Direct ophthalmic medical costs
| |
|
Ranibizumab therapy (81.3% bilateral)
|
$79,056
|
|
Direct non-ophthalmic medical costs
|
|
Injury reduction
|
(−$664)
|
|
Depression reduction
|
(−$2543)
|
|
SNF cost decrease
|
(−$4100)
|
|
Unexplained medical cost decrease
|
(−$28,598)
|
|
Nursing home
|
(−$19,069)
|
|
Total offsetting costs
|
(−$54,974)
|
|
Total direct medical costs
|
$24,082
|
|
Direct non-medical costs
|
|
Paid caregiver salariesa
|
(−$82,419)
|
|
Salary gain for freed-up caregivers now able to take up gainful employment
|
(−$215,123)
|
|
Total direct non-medical costs
|
(−$297,542)
|
|
Indirect medical costs
|
|
Mean patient wage gain
|
(−$9057)
|
|
Total societal costs
|
(−$282,517)
|
